Your partner for Drug Development
Your partner for Drug Development
Your perfect ally for drug discovery
Accelera is a premium tier Contract Research Organization (CRO) working and collaborating
with more than 300 pharmaceutical and biotechnology companies around the world.
We are involved in preclinical research with decades of experience in the international pharmaceutical field helping us to select the best drugs.
We are a Contract Research Organisation (CRO), one of the few Italian companies capable of providing support through all phases of drug research and development, adapting and personalising services and consultancy in accordance with requests.
Our research teams integrate scientific, technological, and regulatory expertise flexible and customized services.
We collaborate internationally with both biotechnology and pharmaceutical companies, as well as with the academic and non-profit world.
Accelera is a subsidiary of the NMS Group.
Our Services as a CRO
Our established scientific experience and flexible, safe, and integrated approach make Accelera the ideal partner for your company to achieve effective, high-quality, and fast results.
We provide scientific advice in special technological areas: from preclinical testing to safety pharmacology and drug interactions, from in vitro tests to radiosynthesis, up to PBPK and PK / PD modelling.
We can also provide support services for New Chemical Entities (NCE) development, biologics as well as new oncology drugs.
Isotope Chemistry & Drug Disposition
Accelera, one stop shop service provider for drug development, offers a unique background, built on years as part of global R&D of Pfizer, Pharmacia & Upjohn and Farmitalia Carlo Erba.
Accelera provides customer tailored services to select the best drug candidates and develop NCEs, NBEs, Biosimilars, and Cell Based Therapies, running optimised IND enabling studies, as well as reproductive toxicology and ADME studies
Fully compliant to international guidelines, Accelera has a strong track record of regulated activities recognized by the major Agencies, including EMA, FDA, KFDA, MHLW.
Look into future
Accelera’s services meet various needs. Our solutions are segmented by molecule type, by the company/institution to which the client belongs, and by the therapeutic area in which it operates, that is, the pathology that the molecule under development is meant to treat.
Identifies the type of molecule (test item) developed by the client and which will be the subject of the studies offered by Accelera’s services. Depending on your molecule type we will choose the most suitable services to create the best drug.
Molecules are divided as follows:
● Small molecule
● Large molecule – Biologic
● Advanced therapy medicinal products (ATMP)
Identifies the type of customer in terms of institution/company. According to the category to which you belong, Accelera will vary the approach and the services offered, taking the key drivers typical of that specific area as a benchmark.
These are the different clients:
● Start up
● Small pharma
● Mid – Large pharma
● Medical device
Identifies the macro-area in terms of pathologies of interest and / or the therapeutic target of the molecule developed by the company or the institution.
These are Accelera’s therapeutic areas of excellence, in which we have gained extensive experience:
Latest News & Events
NMS Group S.p.A. Announces Resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl; Hugues Dolgos – CEO of NMS Group S.p.A. – Appointed Interim CEO
Nerviano, 5 May 2022
NMS Group SpA today announced that its CEO, Hugues Dolgos, has accepted the resignation of Angelo Colombo as CEO of Accelera Srl and NerPharMa Srl, effective 31 May 2022. Hugues Dolgos will act as interim CEO for both companies. A search for a permanent CEO will begin shortly. (Click the title for the complete article)
Member of European Parliament Isabella Tovaglieri and Chairman of the Health Commission of Lombardy Region Emanuele Monti led delegation to visit NMS Group in Nerviano, Lombardy
Nerviano, 7 February 2022
NMS Group, the center of excellence of oncology research and development in the heart of the Lombardy region is honored to receive the visit by Ms. Isabella Tovaglieri, Member of the European Parliament, Mr. Emanuele Monti, Chairman of the Health Commission of Lombardy Region, Mr. Loredano Pollegioni, Chairman of FRRB (Fondazione Regionale per la Ricerca Biomedica), Mr. Luigi Cajazzo, Managing director of FRRB and Mr. Massimiliano Amato, Board member of NMS Group SpA today. The delegation was warmly welcomed by Dr. Hugues Dolgos, the newly appointed CEO of NMS Group and CEOs of the Group’s subsidiaries Dr. Guoxian (Gregory) Wu, Mr. Angelo Colombo, and Mr. Giuseppe Vivolo. (Click the title for the complete article)
NMS Group S.p.A. announces appointment of New CEO Hugues Dolgos and New Board of Directors and CEO of its Subsidiaries
Nerviano, 17 January 2022
The Shareholders’ Meeting of NMS Group S.p.A. (the “Company”) has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are Hugues Dolgos, Raj Sundar, Jianghua (Peter) Zhao, Liping Meng, and Massimiliano Amato.
Following the Shareholders’ Meeting, the Company’s newly formed Board of Directors approved a new governance to accelerate the progression of the portfolio, to strengthen the competitive positions of Accelera and NerPharMa, and to optimize and deliver concrete values for its patients, shareholders, employees and community. Dr. Hugues Dolgos, a seasoned biopharma leader with over 20 years of experience across the R&D value chain from new concept to post approval in multiple therapeutic areas and a proven track record in oncology and immuno-oncology, was appointed as Chief Executive Officer (“CEO”) of the Company, effective immediately. (Click the title to read the complete article)